Key Highlights

  • Cerenome (NASDAQ:CNSY), formerly Plus Therapeutics, was trading up 29.75% at USD 0.9997 on Friday, November 13, 2026, in market data, which implies a prior close near USD 0.77 (calculated); no company announcement explaining the move was found.
  • The stock closed at USD 1.75 on October 22, 2026 according to a market data page, so even after the gain the quote is about 43% lower (calculated).
  • On October 21, 2026 the company described a dual mechanism of action for its lead drug REYOBIQ, citing lethal DNA damage and immunomodulation, and on September 10 it announced a financing Facility of up to USD 20 million.
  • Trailing twelve month Revenue was about USD 4.20 million and the trailing net loss about USD 26.09 million, with about 7.59 million shares outstanding and a Market Value near USD 13.3 million at USD 1.75.

A 29.75% Bounce Without a Company Announcement

Cerenome (NASDAQ:CNSY) was trading up 29.75% at USD 0.9997 on Friday, November 13, 2026, in market data. No company announcement explaining the move was found for November 11 to 13. The company rebranded from Plus Therapeutics in August 2026. It is a clinical-stage pharmaceutical company developing cancer treatments, led by the radiotherapeutic candidate rhenium obisbemeda, and it runs a diagnostics Business through its CNSide subsidiary. With a market value near USD 13.3 million as of October 22, a small number of trades can move the price. Cerenome is the successor name to Plus Therapeutics, whose ticker was PSTV, so older filings may carry the earlier name.

CNSide Rollout and Insurance Coverage

CNSide offers cerebrospinal fluid tumor cell and molecular profile tests. The company launched its CNSide CSF molecular profile tests on October 6, 2026, signed an in-network agreement with Florida Blue on October 8 and one with Blue Cross Blue Shield of Michigan on September 22. On September 30 it said it expected USD 1.55 million of CNSide third-quarter gross billings, and on September 16 it named a head of commercial sales for the division. Gross billings are not recognized revenue, since payers may pay less than billed. Coverage by payers matters for diagnostics because reimbursement determines how much of the billed amount is collected.

Royalty-Linked Financing, Losses and the USD 1 Line

On September 10, 2026 the company announced a financing facility of up to USD 20 million with royalty-based repayment, which ties repayment to future royalties rather than only fixed installments. Revenue for 2025 was USD 5.21 million, down about 10.5%, with a net loss of USD 22.39 million. At USD 0.9997 the stock sits just under USD 1.00; a bid below that level for 30 consecutive business days can lead to a Nasdaq deficiency notice, and none was found. Clinical results, financing terms and dilution are the main risks, and quoted gains can reverse.

Where Things Stand

Nothing verified explains the 29.75% bounce. Cerenome (NASDAQ:CNSY) is quoted at USD 0.9997, still about 43% below its October 22 close of USD 1.75 (calculated), so the move may be a partial rebound, though that is an inference. The company has news on its drug, its diagnostics rollout and a USD 20 million facility, but all predate November 11. Watch for a company release, a Nasdaq notice and the next financial report. A move of this size on a sub-USD 1 stock is not by itself evidence of news. Revenue is small against the losses, so funding remains central.